MedTrace Logo

Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I

NCT01040130 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 151

Last updated 2014-07-08

Study results available
· View outcomes & findings →

Summary

To compare the effects of BI 1744 CL versus placebo on exercise tolerance after 6 weeks of treatment in patients with Chronic Obstructive Pulmonary Disease

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Olodaterol (BI 1744)

Comparison of low and high doses on exercise endurance time in COPD patients

DRUG

Olodaterol (BI 1744)

Comparison of low and high doses on exercise endurance time in COPD patients

DRUG

Placebo

Comparison of low and high dose and placebo on exercise endurance time in COPD patients

DRUG

Olodaterol (BI 1744)

Comparison of low and high dose

DRUG

Olodaterol (BI 1744) Placebo

Placebo that represents olodaterol

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2011-04-30

Countries

  • Australia
  • Austria
  • Canada
  • France
  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01040130 on ClinicalTrials.gov